Polydex Pharmaceuticals Limited (NASDAQ: POLXF) is pleased to announce that Rush University Medical Center and Polydex Pharmaceuticals have been granted a patent from the European Patent Office regarding the use of cellulose sulfate (Ushercell) and other sulfated polysaccharides to prevent and treat papilloma virus infections in humans and other mammals. In studies directed by Lourens J.D. Zaneveld, D.V.M. Ph.D, and described in the patent application, Ushercell was shown to be effective in inhibiting both Bovine Papilloma Virus (BPV) and Human Papilloma Virus (HPV) infections.
